# Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

> **NCT00138177** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage III Colon Cancer
- Stage III Rectal Cancer
- Stage IV Colon Cancer
- Stage IV Rectal Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** leucovorin calcium
- **DRUG:** vorinostat
- **DRUG:** fluorouracil

## Key facts

- **NCT ID:** NCT00138177
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138177, "Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00138177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*